Also in the Article



This was a cross-sectional analysis of data from a subset of participants enrolled in the Maternal Vitamin D for Infant Growth (MDIG) Trial in Dhaka, Bangladesh (Trial Registration Number: NCT01924013, clinicaltrials.gov). The MDIG trial was a double-blind, randomized placebo-controlled trial designed to estimate the dose-ranging effects of prenatal vitamin D supplementation (4200 IU/week, 16,800 IU/week, and 28,000 IU/week) and postpartum supplementation (28,000 IU/week among half the women receiving 28,000 IU/week prenatally), vs placebo on infant length at 1 year of age. Participants enrolled in the MDIG trial were co-supplemented with daily calcium (500 mg) and iron and folic acid (66 mg elemental iron, 350 μg folic acid). Detailed descriptions of the methods and results of the trial are described elsewhere (34, 35). Approval for the MDIG trial and biochemical analyses related to the PTH axis was obtained from research ethics committees at the Hospital for Sick Children and the International Center for Diarrheal Disease Research, Bangladesh (icddr,b). Written informed consent was obtained from all participants for participation and storage of biological specimens.

Note: The content above has been extracted from a research article, so it may not display correctly.



Also in the Article

Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.